Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.

Marco Valgimigli,Davide Cao,Dominick J. Angiolillo,Sripal Bangalore,Deepak L. Bhatt,Junbo Ge,James B. Hermiller,Raj Makkar,Franz-Josef Neumann,Shigeru Saito,Héctor Picón,Ralph Toelg,Aziz Maksoud,Bassem M. Chehab,James W. Choi,Gianluca Campo,José M. de la Torre Hernández,Vijay Kunadian,Gennaro Sardella,Holger Thiele,Olivier Varenne,Pascal Vranckx,Stephan Windecker,Yujie Zhou,Mitchell W. Krucoff,Karine Ruster,Yan Zheng,Roxana Mehran,Xience,Xience Investigators

Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.

2021

Abstract Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown. Objectives The pur...

Keywords:

Medicine
Duration (project management)
everolimus eluting stent
Cardiology
Percutaneous coronary intervention
Thrombosis
Internal medicine
Conventional PCI

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations